Vivek Ramaswamy Sells 273,959 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) Stock
Vivek Ramaswamy, a major shareholder of Roivant Sciences Ltd. (NASDAQ:ROIV), sold 273,959 shares at an average price of $11.47, totaling $3,142,309.73. Post-sale, he owns 39,799,611 shares, valued at approximately $456.5 million, marking a 0.68% decrease in his position. The transaction was disclosed to the SEC. Roivant Sciences has a market cap of $7.87 billion and reported a negative EPS of ($0.20) in its last earnings release. Analysts have mixed ratings on the stock, with some predicting growth.
Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) major shareholder Vivek Ramaswamy sold 273,959 shares of the firm's stock in a transaction that occurred on Tuesday, May 6th. The stock was sold at an average price of $11.47, for a total transaction of $3,142,309.73. Following the sale, the insider now directly owns 39,799,611 shares in the company, valued at $456,501,538.17. The trade was a 0.68 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.
Get Roivant Sciences alerts:
Roivant Sciences Stock Performance
- Trump Index: 6 Companies Linked to Trump’s Cabinet Worth Watching
Roivant Sciences stock opened at $11.03 on Friday. The company's fifty day moving average price is $10.48 and its 200 day moving average price is $11.12. The stock has a market capitalization of $7.87 billion, a P/E ratio of -73.53 and a beta of 1.23. Roivant Sciences Ltd. has a 1 year low of $8.73 and a 1 year high of $13.06.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last released its earnings results on Monday, February 10th. The company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. Sell-side analysts predict that Roivant Sciences Ltd. will post -0.92 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of research analysts have weighed in on the stock. Cantor Fitzgerald raised shares of Roivant Sciences to a "strong-buy" rating in a report on Tuesday, March 4th. HC Wainwright restated a "buy" rating and issued a $18.00 price target on shares of Roivant Sciences in a research note on Monday, April 21st.
View Our Latest Stock Report on Roivant Sciences
Hedge Funds Weigh In On Roivant Sciences
A number of hedge funds have recently made changes to their positions in ROIV. Parallel Advisors LLC boosted its stake in shares of Roivant Sciences by 80.5% in the first quarter. Parallel Advisors LLC now owns 2,485 shares of the company's stock worth $25,000 after acquiring an additional 1,108 shares during the last quarter. Russell Investments Group Ltd. lifted its holdings in Roivant Sciences by 478.6% in the 4th quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company's stock valued at $28,000 after purchasing an additional 1,948 shares in the last quarter. Aster Capital Management DIFC Ltd acquired a new stake in Roivant Sciences during the 4th quarter worth $39,000. GAMMA Investing LLC boosted its stake in Roivant Sciences by 57.0% during the 4th quarter. GAMMA Investing LLC now owns 3,548 shares of the company's stock worth $42,000 after purchasing an additional 1,288 shares during the last quarter. Finally, UMB Bank n.a. grew its holdings in shares of Roivant Sciences by 112.7% during the first quarter. UMB Bank n.a. now owns 4,143 shares of the company's stock worth $42,000 after buying an additional 2,195 shares in the last quarter. Institutional investors and hedge funds own 64.76% of the company's stock.
Roivant Sciences Company Profile
(Get Free Report)Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Recommended Stories
- Five stocks we like better than Roivant Sciences
- Stock Market Holidays 2022-2025 - Here’s When the NYSE and NASDAQ Will be Closed
- IBM's AI Offensive: Assessing IBM's Path to Renewed Growth
- Best Aerospace Stocks Investing
- Rockwell Automation: Tailwinds From Onshoring U.S. Production
- Stock Average Calculator
- Is Energy Transfer Undervalued or a Value Trap?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Roivant Sciences Right Now?
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
